View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 5, 2020updated 06 Mar 2020 7:20am

Arcturus Therapeutics partners with medical school for coronavirus vaccine

Arcturus Therapeutics, a RNA medicines company, and Duke-NUS Medical School have partnered to develop a coronavirus Covid-19 vaccine for Singapore.

Arcturus Therapeutics, a RNA medicines company, and Duke-NUS Medical School have partnered to develop a coronavirus Covid-19 vaccine for Singapore.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

The development of this vaccine will be based on Arcturus’s STARR technology and will tap a platform developed at Duke-NUS to enable quick screening of vaccines for effectiveness and safety.

The STARR Technology platform brings together self-replicating RNA with LUNAR, a nanoparticle non-viral delivery system, to generate proteins within the body.

Given the superior immune response and sustained protein expression, the STARR Technology is expected to generate a vaccine response at lower doses as against traditional mRNA vaccines.

This is expected to lead to the ability to treat many people with a single GMP-manufactured production batch.

Arcturus Therapeutics president and CEO Joseph Payne said: “We have observed STARR technology in pre-clinical models to be effective at extraordinarily low doses — greater than 30-fold more efficient than traditional mRNA.  The Arcturus manufacturing process has been applied in multiple large GMP batches of highly pure RNA in our LUNAR-OTC program.  If successful, Arcturus could develop a vaccine capable of vaccinating millions of people for a fraction of the cost of traditional mRNA vaccines.”

Duke-NUS Medical School dean and professor Thomas M Coffman said: “Duke-NUS has been on the front lines in the fight against COVID-19, developing the first serological tests for COVID-19 and was among the first groups to isolate and culture the virus. The partnership with Arcturus Therapeutics combines complementary strengths as we work together to fight this global outbreak.”

The self-replicating RNA-based therapeutic vaccine will stimulate rapid and prolonged antigen expression within host cells, thereby leading to protective immunity against infectious pathogens.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology